文献速递肾小球疾病

转录组学分析揭示狼疮性肾炎联合治疗的新协同机制

Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis.
PubMed 文献 · Kidney Int · 2018-01-01

该研究在MRL/lpr狼疮性肾炎小鼠模型中比较泼尼松、吗替麦考酚酯、他克莫司单药与联合治疗的疗效及肾脏转录组,发现联合治疗肾脏结局优于单药,并揭示其叠加免疫抑制外的肾脏保护分子通路,并在患者肾活检样本中验证。

要点

  • 联合治疗较单药显著改善狼疮性肾炎小鼠肾脏结局。
  • 联合治疗抑制肾脏TLR7表达并强效抑制IL-6/Stat3通路。
  • 他克莫司联合吗替麦考酚酯通过RhoA/Rac1互调稳定足细胞骨架。

核心结论

  • 联合治疗不仅提供叠加免疫抑制,还诱导增强肾脏保护的基因表达和分子通路。

研究设计与样本

  • 采用MRL/lpr狼疮性肾炎小鼠模型,分别给予泼尼松、吗替麦考酚酯、他克莫司单药或联合治疗,并进行肾脏转录组分析。

主要发现

  • 联合治疗较单药显著改善狼疮性肾炎小鼠肾脏结局。
  • 联合治疗抑制狼疮性肾炎小鼠肾脏TLR7表达。
  • 他克莫司联合吗替麦考酚酯通过互调RhoA和Rac1活性更好稳定足细胞肌动蛋白骨架。
  • 联合治疗强效抑制IL-6/Stat3通路。
  • 上述发现在患者肾活检样本治疗前后得到验证。

临床怎么用

  • 为含吗替麦考酚酯、他克莫司和激素的联合方案治疗重症狼疮性肾炎提供分子机制支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A recent clinical study showed that combination therapy consisting of mycophenolate mofetil, tacrolimus and steroids was shown to be more effective in achieving complete remission in patients with severe forms of lupus nephritis than conventional therapy consisting of intravenous cyclophosphamide and steroids. To explore the underlying molecular and cellular mechanisms of increased efficacy of the combination therapy regimen, we employed a mouse model of lupus nephritis, MRL/lpr mice, and treated them with monotherapies of prednisone, mycophenolate mofetil, or tacrolimus, or with their combination. Consistent with previous clinical findings, combination therapy markedly improved renal outcome compared to the monotherapies in mice with lupus nephritis. Transcriptomic analysis of their kidneys revealed distinct molecular pathways that were differentially regulated in combination therapy versus monotherapies. Combination therapy not only provided additive immunosuppressive effects, but also induced gene expression and molecular pathways to confer enhanced renoprotection. Specifically, combination therapy inhibited TLR7 expression in the kidneys of mice with lupus nephritis; combination of tacrolimus and mycophenolate mofetil led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities. Combination therapy strongly suppressed the IL-6/Stat3 pathway. These findings were further validated in renal biopsy samples from patients with lupus nephritis before and after treatments with mycophenolate mofetil, tacrolimus or combination therapy. Thus, our study further supports the earlier clinical finding and further provides insights into the molecular basis for increased efficacy of combination therapy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Fu J, Wang Z, Lee K, et al. Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney Int. 2018. PMID: 29102373. doi:10.1016/j.kint.2017.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。